Redeye provides an update on Kontigo Care following its Q2 2023 report. The current market conditions continue to bring forth challenges, and Kontigo Care decreased its base of licenses during the quarter. On the bright side is high business activity, the successful completion of clinical studies for mobile phone-based drug monitoring, and the forthcoming effects of price increases. Our near-term financial forecast has undergone minor adjustments, and our fair value range remains unchanged, with a base case of SEK9.5 per share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Kontigo Care - No trend changes

© Modular Finance, source Nordic Press Releases